1. Catalog
  2. OnDemand: Grand Rounds- March 2026: Breaking the O ...
OnDemand: Grand Rounds- March 2026: Breaking the Obesity-Cancer Link with GLP-1RAs
Create Account
Availability
On-Demand
Cost
Member: $0.00
Non-Member: $50.00
Credit Offered
1 AMA PRA Category 1 Credit
This webinar will explore the biologic links between obesity and cancer, highlighting how excess adiposity drives tumor growth via inflammation, immunosuppression, and metabolic dysregulation. We’ll examine the evidence behind calorie restriction and emerging anti-obesity therapies, including GLP-1–based treatments, and their potential to interrupt these pathways and reduce cancer risk.
1. Describe the mechanistic links between obesity and cancer, including the roles of metabolic dysfunction, chronic inflammation, and immune dysregulation in tumor development and progression.
2. Evaluate the evidence for weight-loss interventions, including dietary strategies, bariatric surgery, and GLP-1 receptor agonists, and their potential to influence obesity-related cancer pathways and inform approaches to cancer prevention and treatment.
Stephen D. Hursting PhD
Professor at the University of North Carolina (UNC)
Dr. Stephen Hursting is the AICR/WCRF Distinguished Professor of Nutrition and Cancer in the Department of Nutrition, the Nutrition Research Institute and the Lineberger Comprehensive Cancer Center at the University of North Carolina (UNC) at Chapel Hill.  He earned his PhD in nutritional biochemistry and MPH in nutritional epidemiology from UNC-Chapel Hill, and he completed postdoctoral training in molecular carcinogenesis and cancer prevention at the National Cancer Institute (NCI).  His research interests center on diet-gene interactions relevant to cancer prevention, particularly the molecular and metabolic mechanisms underlying obesity- cancer associations, and the interplay between obesity, metabolism and cancer.
The Obesity Society is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

The Obesity Society designates this enduring material for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Date of Release: April 15, 2026
Date of Termination: December 31, 2028
No commercial support was received for this activity.
Stephen Hursting, PhD, MPH: No relevant financial relationships.
Sriram Machenini, MD: No relevant financial relationships
No members of the TOS CME Oversight Committee, charged with the resolution of all relevant conflicts of interest, had any relevant financial relationships while serving on the committee.
1. Kong W, Deng B, Shen X, John C, Haag J, Sinha N, Lee D, Sun W, Chen S, Zhang H, Clontz A, Hursting SD, Zhou C, Bae-Jump V. Tirzepatide as an innovative treatment strategy in a pre-clinical model of obesity-driven endometrial cancer. Gynecol Oncol. 2024 Dec;191:116-123. doi: 10.1016/j.ygyno.2024.10.004. Epub 2024 Oct 10. PMID: 39388742; PMCID: PMC12419173.

2. Camp KK, Coleman MF, McFarlane TL, Doerstling SS, Khatib SA, Rezeli ET, Lewis AG, Pfeil AJ, Smith LA, Bowers LW, Fouladi F, Gong W, Glenny EM, Parker JS, Milne GL, Carroll IM, Fodor AA, Seeley RJ, Hursting SD. Calorie restriction outperforms bariatric surgery in a murine model of obesity and triple-negative breast cancer. JCI Insight. 2023 Sep 12;8(19): e172868. doi: 10.1172/jci.insight.172868. PMID: 37698918; PMCID: PMC10629811.

3. Valencia-Rincón E, Rai R, Chandra V, Wellberg EA. GLP-1 receptor agonists and cancer: current clinical evidence and translational opportunities for preclinical research. J Clin Invest. 2025 Nov 3;135(21): e194743. doi: 10.1172/JCI194743. PMID: 41178720; PMCID: PMC12578377.

4. Hursting SD. Obesity, energy balance, and cancer: a mechanistic perspective. Cancer Treat Res. 2014;159:21-
33. doi: 10.1007/978-3-642-38007-5_2. PMID: 24114472.
Powered By